# A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

> **NCT01756638** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 48 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT01756638
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-06
- **Primary completion:** 2014-10-17
- **Final completion:** 2014-10-17
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01756638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01756638, "A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT01756638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*